Altos Labs Acquires Dorian Therapeutics

Biogen Acquires Alcyone Therapeutics

September 19, 2025

Medical Devices

Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.

Novartis Acquires DTx Pharma

July 17, 2023

Biotechnology

Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.

Aileron Therapeutics Acquires Lung Therapeutics

October 31, 2023

Biotechnology

Aileron Therapeutics, Inc. (NASDAQ: ALRN) completed a stock-for-stock acquisition of Lung Therapeutics, Inc., bringing the clinical-stage pulmonary and fibrosis-focused pipeline (including lead candidate LTI-03) into Aileron's portfolio. Immediately after the acquisition Aileron arranged a private placement led by Bios Partners (with participation from Nantahala Capital and others) to raise approximately $18 million to fund ongoing development, including a Phase 1b trial of LTI-03.

Danforth Advisors Acquires Elite BioPharma Consulting

September 6, 2023

Healthcare Services

Danforth Advisors has acquired Elite BioPharma Consulting to expand its Development Strategy & Operations (DS&O) practice, adding clinical development operations, project and trial management, clinical monitoring, program management, regulatory affairs, and medical writing capabilities. The founders of Elite will continue to lead the team as Danforth integrates Elite's expertise into its variable resource model for life science companies.

AlphaRose Therapeutics Acquires Alpha Anomeric SA

April 29, 2025

Biotechnology

AlphaRose Therapeutics has acquired Alpha Anomeric SA, a Paris-based developer of the abcDNA oligonucleotide chemistry platform. The acquisition brings a proprietary antisense oligonucleotide chemistry into AlphaRose's portfolio and establishes a European presence to support global development of its neurogenetic and rare-disease programs. Terms were not disclosed.

Boehringer Ingelheim Acquires Nerio Therapeutics

August 6, 2024

Biotechnology

Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.